Home / Peptides / Abaloparatide
Abaloparatide: FDA status and clinical evidence
Abaloparatide is approved by the FDA and is on the US market, first approved April 28, 2017, under 1 application. 25 studies are registered on ClinicalTrials.gov, reaching Phase 4. 9 unexpired patents are listed in the Orange Book.
FDA approval status
FDA review documents
Clinical evidence
By phase
Patents and generic availability
Molecular identity
AVK0I6HY2UAVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTAFrom the FDA Global Substance Registration System, the registry that assigns every substance the FDA tracks a unique identifier.
Frequently asked questions
Is Abaloparatide FDA-approved?
Yes. Abaloparatide holds FDA approval and is marketed in the US. Approval covers the specific uses, doses and forms on the FDA label, not every use it is sold or discussed for.
How much clinical research is there on Abaloparatide?
25 studies are registered on ClinicalTrials.gov with Abaloparatide as an intervention, 13 of them completed. The highest phase reached is Phase 4. Registration counts research activity, not proven benefit.
What brand names is Abaloparatide sold under?
FDA records list TYMLOS. Brand availability changes over time, and some applications on file are marked discontinued.
Where does the information on this page come from?
Four FDA and NIH sources: Drugs@FDA for approval records, the FDA Orange Book for patents and exclusivity, the FDA Global Substance Registration System for molecular identity, and ClinicalTrials.gov for trial counts. Each is refreshed on a schedule and the date above shows the last refresh.
Sources: Drugs@FDA, FDA Orange Book, FDA Global Substance Registration System and ClinicalTrials.gov. Last refreshed 2026-10-16.